|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Morphologic evaluation and FISH for MDM2 amplification should allow its distinction from liposarcoma and other mimics.
|
30826321 |
2019 |
|
Adult Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sensitive assays to detect genomic alterations in cfDNA of synovial sarcomas (t(X;18)), myxoid liposarcomas (t(12;16) and TERT C228T promoter mutation) and well-differentiated/de-differentiated liposarcomas (MDM2 amplifications) were established. ctDNA was quantified in nine liposarcoma patients during the course of their treatment.
|
30779112 |
2019 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In order to clarify the relationship between esophageal liposarcoma and giant fibrovascular polyp, we retrieved esophageal cases coded as 'giant fibrovascular polyp,' 'lipoma' and 'liposarcoma' from our archives and re-examined their clinicopathologic features and MDM2 amplification status.
|
28984298 |
2018 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The observed clinical activity (partial response and prolonged progression-free survival) provides an impetus for further study of HDM2 inhibitors in liposarcoma.
|
28240971 |
2017 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus a pre-operative biopsy was performed along with MDM2 gene amplification to rule out a liposarcoma preceding surgical excision.
|
28088193 |
2017 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We identified patient-specific genetic alterations in candidate driving genes: RASA2 and NF1 (prostate cancer), TP53 and CDKN2C (olfactory neuroblastoma), FAT1, NOTCH1, and SMAD4 (head and neck cancer), KRAS (urachal carcinoma), EML4-ALK (lung cancer), and MDM2 and PTEN (liposarcoma).
|
26925973 |
2016 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Included are seven cell lines with wild-type p53 (four mesothelioma, one breast cancer, one chondrosarcoma, and one leiomyosarcoma), two liposarcoma cell lines harboring MDM2 amplification and wild-type p53, and one mesothelioma cell line harboring a p53 point mutation.
|
27129163 |
2016 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As MDM2 amplification is not specific for the diagnosis of liposarcoma, we investigated its occurrence in 43 cases of endometrial stromal tumors: 14 uterine LG-ESS, 11 metastatic or recurrent uterine LG-ESS, 8 undifferentiated uterine sarcomas, 5 endometrial stromal nodules, and 4 high-grade ESS with YHWAE rearrangement.
|
26444253 |
2015 |
|
Adult Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To the best of our knowledge, this is the first report of MDM2 FISH amplification in a liposarcoma performed on an aspirate smear.
|
25132684 |
2015 |
|
Adult Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, these profiles did not segregate by histology (lung adenocarcinoma-appendiceal cancer (KRAS G12D and GNAS R201C), and lung adenocarcinoma-liposarcoma (CDK4 and MDM2 amplification pairs)).
|
26418953 |
2015 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using fluorescent in situ hybridization (FISH), we sought to characterize various patterns of MDM2 amplification among the morphologic spectrum of liposarcoma.
|
24515760 |
2014 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MDM2 inhibition activates the P53 pathway and decreases cell proliferation in MDM2-amplified liposarcoma.
|
23084521 |
2012 |
|
Adult Liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Well-differentiated LS is characterized by overexpression of MDM2, which blocks the tumor suppressor function of p53.
|
21932353 |
2012 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Also, MDM2 is known to be amplified in several types of mesenchymal tumors, including liposarcoma.
|
21666577 |
2011 |
|
Adult Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, we observed a strong association of malignancy with TP53 mutation, or MDM2 amplification and the presence of a G allele in SNP309, especially in lipoma versus liposarcoma.
|
21159888 |
2011 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MDM2 amplification is one of the earliest events in liposarcoma development, and these results suggest that c-Jun was amplified at a similar time in the evolution of the tumour.
|
19449367 |
2009 |
|
Adult Liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Prognostic factors and expression of MDM2 in patients with primary extremity liposarcoma.
|
18438568 |
2008 |
|
Adult Liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Chromosome-12 copy number alterations and MDM2, CDK4 and TP53 expression in soft tissue liposarcoma.
|
17214366 |
2007 |
|
Adult Liposarcoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, alterations of mdm2 and p53 genes belong to the most frequently reported alterations in these two subtypes of liposarcoma.
|
12924448 |
2003 |
|
Adult Liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Lipoma was characterized by a lack of p53 mutation, p53 LOH and p53 protein expression, as well as by mdm2 amplification and mdm2 protein expression. p53 mutation and p53 LOH were found neither in the well-differentiated nor in the dedifferentiated parts of the liposarcoma.
|
11518050 |
2001 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The findings in this study agree with the molecular data and they show the physical association of mdm2 and p53 in fresh liposarcoma surgical specimens.
|
10565683 |
1999 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As well as confirming the synergistic effect of MDM2 and CDK4, these results are consistent with the concept that amplicon(s) excluding MDM2 may contribute to transformation and support a role of CDK4 in opposing p53 function, particularly in NR WD liposarcoma.
|
9713346 |
1998 |
|
Adult Liposarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
|
9071998 |
1997 |
|
Adult Liposarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Such a finding contrasts with the higher rates of p53/MDM2 abnormalities reported in other types of sarcomas such as liposarcoma.
|
8644845 |
1996 |